Plexium

Please note: The information displayed on this page might be outdated.
Plexium: Plexium is an emerging biotechnology company focused on the rational design of monovalent protein degrading therapeutics to treat cancer and other serious diseases. Plexium’s targeted protein degradation platform, DELPhe®, enables the discovery of novel small molecules with cell-based activity that redirect E3 ligases to pathogenic proteins of interest or induce degradation of pathogenic proteins by directly binding to them. Plexium is advancing a pipeline of wholly-owned targeted oncology and immune-oncology drug candidates. In addition, Plexium has an active drug discovery collaboration with Amgen to discover novel E3 ligase modulating small molecule therapeutics.
Sector/Industry:
Biotech Company
Characteristics:
Based in...
North America
Listing
Private
Website:
Address:
United States

Company Participants at Fall Private Company Showcase 2021

  • Kevin Eastwood, Vice President, Business Development